Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586898 · ClinicalTrials.gov registry record · Phase 2
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00586898: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00586898 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586898, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Objective: To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.
Primary Outcome
Complete Response: Normalization of the PSA (\< or = to 4.0 for patients with castrate metastatic disease, or \< 0.5 for patients with a rising PSA) that is maintained on 3 successive evaluations a minimum of 2 weeks apart. Partial Response: Decrease in PSA value by \> or = to 50% from baseline value (without normalization) for 3 successive evaluations a minimum of 2 weeks apart. Stabilization: Patients who do not meet the criteria for PR or PROG for at least 90 days will be considered stable.
Interventions
- DRUG Bicalutamide
- DRUG GnRH
- DRUG Ketoconazole
- DRUG Testosterone transdermal gel
- DRUG Estrogen transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2001-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
What the finished NCT00586898 record still lists
NCT00586898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 5 interventions - of which Bicalutamide is the first listed.
NCT00586898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00586898 about?
NCT00586898 is a clinical study titled "Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle". Objective: To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.
What is the current status of trial NCT00586898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2001-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00586898?
The interventions under investigation include: Bicalutamide (DRUG), GnRH (DRUG), Ketoconazole (DRUG), Testosterone transdermal gel (DRUG), Estrogen transdermal patch (DRUG).
Who is sponsoring clinical trial NCT00586898?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00586898's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia